Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer

INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer. METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study....

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Thorac Oncol
Main Authors: Choong, Nicholas W., Mauer, Ann M., Haraf, Daniel J., Lester, Eric, Hoffman, Philip C., Kozloff, Mark, Lin, Shang, Dancey, Janet E., Szeto, Livia, Grushko, Tatyana, Olopade, Olufunmilayo I., Salgia, Ravi, Vokes, Everett E.
Formato: Artigo
Idioma:Inglês
Publicado: 2008
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535721/
https://ncbi.nlm.nih.gov/pubmed/18758303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818396a4
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares